GSK and Moderna Settle Vaccine Patent Disputes
British drugmaker GSK and Moderna have settled lawsuits regarding patents for COVID-19 and RSV vaccines. The companies granted cross-licenses without any financial payments and asked a US court to dismiss the claims.
Xurve View
Perspectivas:
Xurve View
GSK PLC-SPON ADR settled patent disputes with MODERNA INC on October 28, resolving allegations that Spikevax, mNEXSPIKE, and mResvia infringed its mRNA technology. The agreement spans courts in the United States and Europe without financial penalties.
